Federal Circuit

PATENT, TRADE - The Federal Circuit found that imported recombinant human erythropoietin was properly held as exempt from patent infringement by the safe-harbor statute, but that defendants' uses of imports unrelated to obtaining FDA approval are not shielded. The International Trade Commission should not have dismissed the issue on jurisdictional grounds.

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Email *

Submit